Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARE: ctDNA-guided Second Line Adjuvant Therapy for High Risk ER+/HER2- Breast Cancer
NCT04567420Phase 2Active, not recruiting
- Sponsor
- Criterium
- Start
- Feb 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of palbociclib and fulvestrant in breast cancer (2 arms), sponsored by Criterium. Primary endpoints: Surveillance/ctDNA screening Phase and Therapeutic Phase at 6 years. Started Feb 2021; status: active, not recruiting.
02
Drugs
palbociclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04567420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04567420.